Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran
Conditions: Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters Interventions: Drug: Dabigatran Etexilate 150mg Sponsors: The Affiliated Hospital Of Guizhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults
Conditions: Health Interventions: Drug: Dabigatran Etexilate; Dietary Supplement: D-mannose Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
Conditions: Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers Interventions: Drug: BAY2927088; Drug: Dabigatran etexilate; Drug: Rosuvastatin Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients
Conditions: Diabetes Interventions: Drug: The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach. Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants Concentration Among Patients With Acute Stroke (The Direct Oral AntiCoagulant Registry in Taiwan-Emergent Department, DOACT-ED)
Conditions: Assess the Stroke Outcome in DOAC Users Who Suffered From Ischemic Stroke or Intracranial Hemorrhage Interventions: Drug: Dabigatran, rivaroxaban, apixaban, edoxaban Sponsors: National Taiwan University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Evaluataion of NOAC Levels in Acute Stroke
Conditions: Ischemic Stroke; Anticoagulant Adverse Reaction Interventions: Drug: Dabigatran, rivaroxaban, apixaban, edoxaban Sponsors: National Taiwan University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
Condition: Venous Thromboembolism Intervention: Sponsors: Boehringer Ingelheim; Children's Hospital Acquired Thrombosis consortium Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Condition: Healthy Interventions: Drug: Camlipixant + Gemfibrozil; Drug: Dabigatran etexilate + camlipixant Sponsor: Bellus Health Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 25, 2023 Category: Research Source Type: clinical trials
